Aprepitant

阿瑞匹坦

Report date: 2025/12/02 11:37:35
NMEFirst In Class

Base Information

Drug NameAprepitant
Drug Alias NameAprepitantum阿瑞吡坦阿瑞比坦阿瑞匹坦亚微乳制剂（齐鲁）Emend +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeurokinin 1 receptor antagonists
TargetsNeurokinin 1 receptor
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Chemotherapy-induced nausea and vomitingStress Disorders, Post-Traumatic +[19] 
Global Approved IndicationsChemotherapy-induced nausea and vomiting
Approved Indications in ChinaChemotherapy-induced nausea and vomiting
Original Approved Country/TerritoryUnited States
Original Approved Date2003/03/26
Country/TerritoryCanadaUnited StatesTurkey +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesOxilio LtdHeron Therapeutics IncMerck Sharp & Dohme Bv +[8] 
Inactive CompaniesHeron TherapeuticsNational Institute On Alcohol Abuse And AlcoholismNational Institute On Drug Abuse +[12] 
Active IndicationsChemotherapy-induced nausea and vomitingVomitingNausea +[5] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Stress Disorders, Post-TraumaticDepressive Disorder, Major +[14] 

Other Information

ATC CodeA04AD12
Related LinksWikipediaDrugBankKEGG